Wealth High Governance Capital’s Vertex Pharmaceuticals VRTX Stock Holding History

Wealth High Governance Capital’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-15,528	Closed	-$6.25M	–	55
2024 Q4	$6.25M	Buy	+15,528	New	+$7.2M	2.24%	21
2024 Q3	–	Sell	-30,000	Closed	-$14.1M	–	64
2024 Q2	$14.1M	Buy	30,000 +18,000	+150%	+$7.81M	3.49%	10
2024 Q1	$5.02M	Sell	12,000 -68,000	-85%	-$28.7M	1.12%	36
2023 Q4	$32.6M	Buy	+80,000	New	+$29.6M	14.01%	1
2023 Q2	–	Sell	-6,000	Closed	-$1.89M	–	33
2023 Q1	$1.89M	Buy	+6,000	New	+$1.8M	0.84%	19

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Wealth High Governance Capital's VRTX Position: Q1 2025 in Review

Wealth High Governance Capital sold out of Vertex Pharmaceuticals (VRTX) in Q1 2025, closing a stake of 15,528 shares — an estimated $6.25M sold.

Wealth High Governance Capital first reported a position in VRTX in Q1 2023 and held it in 5 quarters. The position peaked at $32.6M in Q4 2023. 1,612 funds tracked by Wall St. Rank hold VRTX as of Q1 2025.

Wealth High Governance Capital reported no remaining Vertex Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Wealth High Governance Capital sold 15,528 Vertex Pharmaceuticals shares in Q1 2025, an estimated $6.25M.
Wealth High Governance Capital first reported a position in Vertex Pharmaceuticals in Q1 2023 and held it in 5 quarters.
Wealth High Governance Capital's Vertex Pharmaceuticals position peaked at $32.6M in Q4 2023.
1,612 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2025.

Based on Wealth High Governance Capital's 13F filing for Q1 2025, filed 15 May 2025.